UB Paderborn / Katalog / Suche / in CDI

1 – 23 von 23

Sortiert nach

CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24), p.10288-10298

2010

Link zum Volltext

Verfügbarkeit prüfen

Anticancer Activity of CX-3543: A Direct Inhibitor of rRNA Biogenesis

Cancer research (Chicago, Ill.), 2009-10, Vol.69 (19), p.7653-7661

2009

Link zum Volltext

Verfügbarkeit prüfen

CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy

Molecular cancer therapeutics, 2012-04, Vol.11 (4), p.994-1005

2012

Link zum Volltext

Verfügbarkeit prüfen

Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer

Molecular and cellular biochemistry, 2011-10, Vol.356 (1-2), p.37-43

2011

Link zum Volltext

Verfügbarkeit prüfen

Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer

Biochemical and biophysical research communications, 2011-11, Vol.415 (1), p.163-167

2011

Link zum Volltext

Verfügbarkeit prüfen

Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells

Cancer letters, 2012-09, Vol.322 (1), p.113-118

2012

Link zum Volltext

Verfügbarkeit prüfen

Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics

ACS medicinal chemistry letters, 2012-07, Vol.3 (7), p.602-606

2012

Link zum Volltext

Verfügbarkeit prüfen

Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases Inhibitor

ACS medicinal chemistry letters, 2012-02, Vol.3 (2), p.135-139

2012

Link zum Volltext

Verfügbarkeit prüfen

Targeting RNA Polymerase I with an Oral Small Molecule CX-5461 Inhibits Ribosomal RNA Synthesis and Solid Tumor Growth

Cancer research (Chicago, Ill.), 2011-02, Vol.71 (4), p.1418-1430

2011

Link zum Volltext

Verfügbarkeit prüfen

Design and Discovery of a Potent and Selective Inhibitor of Integrin αvβ1

Journal of medicinal chemistry, 2024-06, Vol.67 (12), p.10306-10320

2024

Link zum Volltext

Verfügbarkeit prüfen

Biochemical and Cellular Profile of NIK Inhibitors with Long Residence Times

SLAS discovery, 2021-06, Vol.26 (5), p.676-683

2021

Link zum Volltext

Verfügbarkeit prüfen

CX-4945, a Selective and Orally Bioavailable Inhibitor of Protein Kinase CK2 Inhibits PI3K/Akt, JAK-STAT and NF-κB Signaling and Induces Apoptosis In Multiple Myeloma Cells

Blood, 2010-11, Vol.116 (21), p.787-787

2010

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3765: Discovery and biological characterization of CX-8184, a potent inhibitor of protein kinase CK2

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.3765-3765

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4511: CX-5461, a non-genotoxic activator of p53 through selective inhibition of RNA polymerase I for the treatment of hematological cancers

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.4511-4511

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2560: The CK2 inhibitor CX-4945 enhances the antitumor activity of EGFR-targeted agents by attenuating signaling in the PI3K/AKT/mTOR pathway

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.2560-2560

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract PR15: Inhibition of RNA Polymerase I as a therapeutic strategy for cancer-specific activation of p53

Cancer research (Chicago, Ill.), 2011-09, Vol.71 (18_Supplement), p.PR15-PR15

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract C198: CX-4945, a novel small molecule inhibitor of CK2 protein kinase, reduces hyperactivated Akt signaling and synergizes with Akt inhibitors in breast cancer cells

Molecular cancer therapeutics, 2009-12, Vol.8 (12_Supplement), p.C198-C198

2009

Link zum Volltext

Verfügbarkeit prüfen

In-orbit Performance of the Near-infrared Spectrograph NIRSpec on the James Webb Space Telescope

Publications of the Astronomical Society of the Pacific, 2023-03, Vol.135 (1045), p.38001

2023

Link zum Volltext

Verfügbarkeit prüfen

Development of a ring PET insert for MRI

2013 IEEE Nuclear Science Symposium and Medical Imaging Conference (2013 NSS/MIC), 2013, p.1-9

2013

Link zum Volltext
IEEE_Xplore

AAOHN Competencies

Workplace health & safety, 2015-11, Vol.63 (11), p.484-492

2015

Link zum Volltext

Verfügbarkeit prüfen

Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders 1 1This study was registered with ClinicalTrials.gov (trial registry no. NCT00006157)

Gastroenterology (New York, N.Y. 1943), 2003-07, Vol.125 (1), p.19-31

2003

Link zum Volltext

Verfügbarkeit prüfen

1 – 23 von 23

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(22)
Tagungsberichte
(1)

Sprache

Englisch
(23)
Japanisch
(11)

Erscheinungsjahr

n.n

Thema

Science & Technology
(16)
Life Sciences & Biomedicine
(15)
Humans
(10)
Animals
(9)
Mice
(9)
Cell Line, Tumor
(7)
Female
(7)
Naphthyridines - Pharmacology
(7)
Oncology
(7)
Casein Kinase Ii - Antagonists & Inhibitors
(6)
Cancer Research
(5)
Xenograft Model Antitumor Assays
(5)
Biochemistry
(4)
Chemistry, Medicinal
(4)
Neoplasms - Drug Therapy
(4)
Neoplasms - Genetics
(4)
Pharmacology & Pharmacy
(4)
Administration, Oral
(3)
Antineoplastic Agents - Pharmacology
(3)
Apoptosis
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy

Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53

Anticancer Activity of CX-3543: A Direct Inhibitor of rRNA Biogenesis

Discovery and SAR of 5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the First Clinical Stage Inhibitor of Protein Kinase CK2 for the Treatment of Cancer

CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy

Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer

Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer

Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells

Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics

Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases Inhibitor

Targeting RNA Polymerase I with an Oral Small Molecule CX-5461 Inhibits Ribosomal RNA Synthesis and Solid Tumor Growth

Design and Discovery of a Potent and Selective Inhibitor of Integrin αvβ1

Biochemical and Cellular Profile of NIK Inhibitors with Long Residence Times

CX-4945, a Selective and Orally Bioavailable Inhibitor of Protein Kinase CK2 Inhibits PI3K/Akt, JAK-STAT and NF-κB Signaling and Induces Apoptosis In Multiple Myeloma Cells

Abstract 3765: Discovery and biological characterization of CX-8184, a potent inhibitor of protein kinase CK2

Abstract 4511: CX-5461, a non-genotoxic activator of p53 through selective inhibition of RNA polymerase I for the treatment of hematological cancers

Abstract 2560: The CK2 inhibitor CX-4945 enhances the antitumor activity of EGFR-targeted agents by attenuating signaling in the PI3K/AKT/mTOR pathway

Abstract PR15: Inhibition of RNA Polymerase I as a therapeutic strategy for cancer-specific activation of p53

Abstract C198: CX-4945, a novel small molecule inhibitor of CK2 protein kinase, reduces hyperactivated Akt signaling and synergizes with Akt inhibitors in breast cancer cells

In-orbit Performance of the Near-infrared Spectrograph NIRSpec on the James Webb Space Telescope

Development of a ring PET insert for MRI

AAOHN Competencies

Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders 1 1This study was registered with ClinicalTrials.gov (trial registry no. NCT00006157)

Suchergebnisse filtern